In focus · trending topic

Edgar

31 stories · following the connections

Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

By Nasdaq OMXFeb 22, 2018, 9:35 PM UTC

Arbutus Enters Exclusivity Agreement with Roivant Sciences

By Nasdaq OMXFeb 15, 2018, 1:50 AM UTC

Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

By Nasdaq OMXFeb 14, 2018, 2:36 AM UTC

Arbutus Consolidates HBV Business Around Warminster, PA Site

By Nasdaq OMXFeb 8, 2018, 1:32 PM UTC

Arbutus Announces Presentations at HepDART 2017

By Nasdaq OMXNov 27, 2017, 2:01 PM UTC

Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran

By Nasdaq OMXNov 16, 2017, 6:40 PM UTC

Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results

By Nasdaq OMXNov 2, 2017, 8:00 PM UTC

Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results

By Nasdaq OMXOct 31, 2017, 10:16 PM UTC